Finnrick, an independent testing programme, publishes 8 assays for Guangzhou Aoyu: 5 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 3 did not. Most recent assay 26 Jun 2026.
Guangzhou Aoyu listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/guangzhou-aoyu.
Guangzhou Aoyu is listed as active.
No independent third-party assay is on file for Guangzhou Aoyu, and we have not yet compiled a profile of its own website. An untested vendor has not failed a test — this is an absence of evidence, not evidence against it.
| Product | Assays | Result |
|---|---|---|
| Tirzepatide | 8 | 5 passed, 3 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
Guangzhou Aoyu is listed as active and we hold 8 Finnrick assays (5 passing, 3 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 8 assays for Guangzhou Aoyu: 5 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 3 did not. Most recent assay 26 Jun 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Guangzhou Chongshan Medical Technology Peptides Review, Guangzhou Cosmetics Factory Peptides Review, Guangzhou Gemini Biotech GGB Peptides Review.